• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Becton Dickinson and Company

    5/7/26 4:53:42 PM ET
    $BDX
    Medical/Dental Instruments
    Health Care
    Get the next $BDX alert in real time by email
    S-8 1 forms-82004employeeanddire.htm S-8 2004 EMPLOYEE AND DIRECTOR EQUITY-BASED COMPENSATION PLAN Document

    As filed with the Securities and Exchange Commission on May 7, 2026
    Registration No. 333-
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D.C. 20549 
    FORM S-8
    REGISTRATION STATEMENT
    UNDER THE SECURITIES ACT OF 1933 
    BECTON, DICKINSON AND COMPANY
    (Exact name of registrant as specified in its charter) 
     
    New Jersey22-076120
    (State or other jurisdiction of incorporation or organization)(I.R.S. Employer Identification No.)
    1 Becton Drive
    Franklin Lakes, NJ 07417
    (201) 847-6800
    (Address, Including Zip Code, and Telephone Number, Including Area Code, of Registrant's Principal Executive Offices)

    2004 EMPLOYEE AND DIRECTOR
    EQUITY-BASED COMPENSATION PLAN
    (Full title of the plan)
    Stephanie M. Kelly
    Chief Securities and Governance Counsel, Corporate Secretary
    1 Becton Drive
    Franklin Lakes, New Jersey 07417-1880
    (201) 847-6800
    (Name, address, including zip code, and telephone number, including area code, of agent for service)
    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):
    Large accelerated filer☒Accelerated filer☐Non-accelerated filer☐ Smaller reporting company☐
    Emerging growth company☐
     
    If an emerging growth company, indicate by check mark if the Registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards.☐



    EXPLANATORY NOTE
    Becton, Dickinson and Company (the “Registrant” or the “Company”) filed a Registration Statement on Form S-8 with the U.S. Securities and Exchange Commission (the “SEC”) on August 13, 2004 (Registration No. 333-118235, the “Prior Registration Statement”) to register under the Securities Act of 1933, as amended (the “Securities Act”), shares of Company common stock, par value $1.00 per share (“Common Stock”), issuable under the Becton, Dickinson and Company 2004 Employee and Director Equity-Based Compensation Plan (the “Plan”).
    The Registration Statement has been prepared and filed pursuant to, and in accordance with, the requirements of General Instruction E to Form S-8 for the purpose of effecting the registration under the Securities Act of an additional 5,237,485 shares of Common Stock issuable under the Plan at any time or from time to time.
    The number of shares of Common Stock to be registered pursuant to this Registration Statement (5,237,485) reflects the number of additional shares of Common Stock approved by the Registrant’s shareholders for issuance under the Plan at the Company’s 2026 annual meeting of shareholders on January 27, 2026 (3,935,000), as adjusted to reflect the completion of the spin-off of the Company’s Biosciences & Diagnostic Solutions business and the combination of such business with Waters Corporation on February 9, 2026 (the “Spin-Off”). This adjustment was effected in the same manner as adjustments made to awards outstanding under the Plan at the time of the completion of the Spin-Off and otherwise in accordance with the terms of the documents related to the Spin-Off.
    In accordance with General Instruction E of Form S-8, the contents of the Prior Registration Statement. including any amendments thereto or filings incorporated therein, are incorporated by reference into this Registration Statement to the extent not otherwise amended or superseded by the contents hereof.
    PART II
    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT
    ITEM 3. INCORPORATION OF DOCUMENTS BY REFERENCE.
    This Registration Statement incorporates by reference the Prior Registration Statement and the following documents filed by the Registrant with the SEC, but not included or delivered with this Registration Statement:
    (a)
    the Registrant’s Annual Report on Form 10-K for the fiscal year ended September 30, 2025, filed on November 25, 2025 (the “2025 Annual Report”);
    (b)
    the Registrant’s Quarterly Reports on Form 10-Q for the fiscal quarters ended December 31, 2025 and March 31, 2026, filed on February 9, 2026 and May 7, 2026, respectively;
    (c)
    the Registrant’s Current Reports on Form 8-K filed on October 15, 2025, November 17, 2025, December 1, 2025, January 6, 2026, January 30, 2026, February 5, 2026, February 9, 2026, February 10, 2026, February 25, 2025, April 9, 2026, April 29, 2026 and May 7, 2026, in each case, other than information furnished under Item 2.02 or 7.01 of Form 8-K;
    (d)
    the portions of the Registrant’s Definitive Proxy Statement on Schedule 14A for its 2026 annual meeting of stockholders filed on December 18, 2025 that are incorporated by reference into the 2025 Annual Report; and
    (e)
    the description of the Common Stock, which was filed as Exhibit 4(z) to the 2025 Annual Report, including any amendment or report filed for the purpose of updating such description.
    We are also incorporating by reference all documents filed by the Registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act after the date of this Registration Statement (excluding any documents or



    portions of such documents that are furnished under Items 2.02 or 7.01 of Form 8-K and any related exhibits) and prior to the filing of a post-effective amendment to this Registration Statement which indicates that all securities offered have been sold or which deregisters all securities then remaining unsold, other than any portion of the respective filings furnished, rather than filed, under the applicable SEC rules. The additional information incorporated by reference is a part of this Registration Statement from the date of filing of those documents.
    Any statement contained in a document incorporated by (or deemed incorporated by) reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein (or in any other subsequently filed document which also is or is deemed to be incorporated by reference herein) modifies or supersedes such statement. Any statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.
    The information relating to the Registrant contained in this Registration Statement should be read together with the information in the documents incorporated by reference herein.
    ITEM 5. INTERESTS OF NAMED EXPERTS AND COUNSEL.
    The validity of the securities has been passed upon by Stephanie M. Kelly, Chief Securities and Governance Counsel, Corporate Secretary, of the Registrant. Ms. Kelly beneficially owns shares of Common Stock, has been granted awards under the Plan and is eligible to receive awards under the Plan.
    ITEM 6. INDEMNIFICATION OF DIRECTORS AND OFFICERS.
    Section 3-5 of Title 14A of the New Jersey Business Corporation Act, as amended (the “NJBCA”), stipulates that, unless limited by its certificate of incorporation, by-laws, a resolution of its board of directors or of its shareholders, an agreement or other proper corporate action, in effect at the time of the accrual of the alleged cause of action asserted in a proceeding, which prohibits, limits or otherwise conditions the exercise of indemnification powers by the corporation or the rights of indemnification to which a corporate agent may be entitled, a New Jersey corporation has the power to indemnify a corporate agent against expenses and liabilities in connection with any proceeding, including any proceeding by or in the right of the corporation to procure a judgment in its favor which involves the corporate agent by reason of being or having been such corporate agent, if such agent acted in good faith and in a manner reasonably believed to be in or not opposed to the best interests of the corporation and, with respect to any criminal proceeding, had no reasonable cause to believe such conduct was unlawful. However, in a proceeding by or in the right of the corporation, no indemnification shall be provided in respect of any claim, issue or matter as to which such corporate agent shall have been adjudged to be liable to the corporation, unless and only to the extent that the New Jersey Superior Court or the court in which such proceeding was brought determines upon application that despite the adjudication of liability, but in view of all circumstances of the case, such corporate agent is fairly and reasonably entitled to indemnity for such expenses as the New Jersey Superior Court or such other court shall deem proper. Unless otherwise provided in the corporation’s organizational documents, the determination that the corporate agent is eligible for indemnification pursuant to the NJBCA shall be made: (1) by the board of directors or a committee thereof, acting by a majority vote of a quorum consisting of directors who were not parties to or otherwise involved in the proceeding; (2) if such a quorum is not obtainable, or, even if obtainable and such quorum of the board of directors or committee by a majority vote of the disinterested directors so directs, by independent legal counsel, in a written opinion, such counsel to be designated by the board of directors; or (3) by the shareholders if the certificate of incorporation or bylaws or a resolution of the board of directors or of the shareholders so directs.
    The indemnification and advancement of expenses provided by or granted pursuant to the NJBCA does not exclude any other rights, including the right to be indemnified against liabilities and expenses incurred in proceedings by or in the right of the corporation, to which a corporate agent may be entitled under a certificate of incorporation, bylaw, agreement, vote of shareholders, or otherwise; provided that no indemnification shall be made to or on behalf of a corporate agent if a judgment or other final adjudication adverse to the corporate agent establishes that such agent’s acts or omissions: (1) were in breach of such agent’s duty of loyalty to the corporation



    or its shareholders; (2) were not in good faith or involved a knowing violation of law; or (3) resulted in receipt by the corporate agent of an improper personal benefit.
    The Registrant’s restated certificate of incorporation provides that, to the full extent that applicable law permits the limitation or elimination of the liability of directors, no director or officer will be personally liable to the Registrant or its shareholders for damages for breach of any duty owed to the Registrant or its shareholders.
    The Registrant’s bylaws provide that, to the full extent that applicable law permits the limitation or elimination of the liability of any corporate agent, the Registrant will indemnify any corporate agent involved in any proceeding by reason of the fact that such agent is, or was, a corporate agent of the Registrant. The reasonable expenses incurred by a director or officer in defending or investigating a proceeding will be paid by the Registrant in advance of the final disposition of such proceeding upon receipt of an undertaking (reasonably satisfactory to the Registrant) by or on behalf of such director or officer to repay such amount if it shall ultimately be determined that such person is not entitled to be indemnified by the Registrant.
    Any indemnification under the Registrant’s bylaws will be made by the Registrant only as authorized in the specific case upon a determination that indemnification of the corporate agent is proper in the circumstances, because such person has met the applicable standard of conduct set forth in the NJBCA. With respect to directors or officers of the Registrant, such determination shall be made: (1) by a majority vote of the directors who are not parties to such proceeding, even though less than a quorum; (2) if there are no such directors, or if such directors so direct, in a written opinion by independent legal counsel designated by the board of directors; or (3) by the shareholders. With respect to all other corporate agents and unless otherwise directed by the board of directors, such determination may be made by the Registrant’s general counsel.
    The Registrant maintains a standard policy of officers’ and directors’ liability insurance.
    The foregoing is only a general summary of certain aspects of New Jersey law and the Registrant’s restated certificate of incorporation and bylaws dealing with indemnification of directors and officers, and does not purport to be complete. It is qualified in its entirety by reference to the detailed provisions of those Sections of the NJBCA referenced above and the restated certificate of incorporation and bylaws of the Registrant.



    ITEM 8. EXHIBITS.
    Exhibit NumberExhibit Description
    3.1
    Restated Certificate of Incorporation of Becton, Dickinson and Company (as restated January 30, 2019) (incorporated by reference to Exhibit 3 to the Registrant’s Quarterly Report on Form 10-Q for the period ended December 31, 2018).
    3.2
    Certificate of Designation of Series D Junior Participating Redeemable Preferred Stock, effective as of January 30, 2026 (incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K filed on February 5, 2026).
    3.3
    By-laws, as amended as of April 28, 2026 (incorporated by reference to Exhibit 3.1 to the registrant’s Current Report on Form 8-K filed on April 29, 2026).
    5.1
    Opinion of Stephanie M. Kelly, Chief Securities and Governance Counsel, Corporate Secretary, of the Registrant (filed herewith).
    10.1
    2004 Employee and Director Equity-Based Compensation Plan, as amended and restated as of January 27, 2026 (incorporated by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K, filed on January 30, 2026).
    23.1
    Consent of Ernst & Young LLP (filed herewith).
    23.2
    Consent of Stephanie M. Kelly, Chief Securities and Governance Counsel, Corporate Secretary, of the Registrant (included in Exhibit 5.1 filed herewith).
    24
    Powers of Attorney (included on signature page of this Registration Statement).
    107.1
    Filing fee table (filed herewith).



    ITEM 9. UNDERTAKINGS.
    (a)    The undersigned Registrant hereby undertakes:
    (1)    To file, during any period in which offers or sales are being made, a post-effective amendment to this Registration Statement:
    (i)    To include any prospectus required by section 10(a)(3) of the Securities Act;
    (ii)    To reflect in the prospectus any facts or events arising after the effective date of this Registration Statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in this Registration Statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than 20 percent change in the maximum aggregate offering price set forth in the “Calculation of Registration Fee” table in the effective Registration Statement; and
    (iii)    To include any material information with respect to the plan of distribution not previously disclosed in this Registration Statement or any material change to such information in this Registration Statement; provided, however, that paragraphs (a)(1)(i) and (a)(1)(ii) of this Item do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Commission by the Registrant pursuant to section 13 or section 15(d) of the Exchange Act that are incorporated by reference in this Registration Statement.
    (2)    That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof; and
    (3)    To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.
    (b)    The undersigned Registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the Registrant’s annual report pursuant to section 13(a) or section 15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan’s annual report pursuant to section 15(d) of the Exchange Act) that is incorporated by reference in this Registration Statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.
    (c)    Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the Registrant pursuant to the foregoing provisions, or otherwise, the Registrant has been advised that in the opinion of the Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.



    SIGNATURES
    Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Franklin Lakes, State of New Jersey, on May 7, 2026.
    BECTON, DICKINSON AND COMPANY
    By:
    /s/ Stephanie M. Kelly
    Stephanie M. Kelly
    Chief Securities and Governance Counsel, Corporate Secretary
    POWERS OF ATTORNEY
    Each person whose signature appears below constitutes and appoints Thomas E. Polen, Lanesha Minnix and Stephanie M. Kelly, and each of them, each of whom may act without the joinder of the other, as his or her true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution, for him or her and in his or her name, place, and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this registration statement, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorney-in-fact and agents full power and authority to do and perform each and every act and thing requisite and necessary to be done, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents or any of them or their substitutes, may lawfully do or cause to be done by virtue hereof.
    Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed by the following persons in the capacities indicated and on the dates indicated below.



    SignatureTitleDate
    /s/ Thomas E. PolenChairman, Chief Executive Officer, President and Director
    (Principal Executive Officer)
    May 7, 2026
    Thomas E. Polen
    /s/ Vitor Roque
    Executive Vice President, Chief Financial Officer (Principal Financial Officer)
    May 7, 2026
    Vitor Roque
    /s/ Pamela SpiknerSenior Vice President, Chief Accounting Officer and Controller
    (Principal Accounting Officer)
    May 7, 2026
    Pamela Spikner
    /s/ William M. BrownDirectorMay 7, 2026
    William M. Brown
    /s/ Carrie L. ByingtonDirectorMay 7, 2026
    Carrie L. Byington
    /s/ R. Andrew EckertDirectorMay 7, 2026
    R. Andrew Eckert
    /s/ Gregory J. HayesDirectorMay 7, 2026
    Gregory J. Hayes
    /s/ Jeffrey W. HendersonDirectorMay 7, 2026
    Jeffrey W. Henderson
    /s/ Robert L. HuffinesDirectorMay 7, 2026
    Robert L. Huffiness
    /s/ Christopher JonesDirectorMay 7, 2026
    Christopher Jones
    /s/ Timothy M. RingDirectorMay 7, 2026
    Timothy M. Ring
    /s/ Bertram L. ScottDirectorMay 7, 2026
    Bertram L. Scott
    /s/ Joanne WaldstreicherDirectorMay 7, 2026
    Joanne Waldstreicher
    /s/ Jacqueline WrightDirectorMay 7, 2026
    Jacqueline Wright

    Get the next $BDX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BDX

    DatePrice TargetRatingAnalyst
    5/4/2026$180.00Outperform
    Evercore ISI
    4/10/2026$167.00Neutral
    Goldman
    2/10/2026$202.00Overweight
    Barclays
    2/3/2026$233.00Buy
    Citigroup
    9/25/2025$211.00Sector Perform
    RBC Capital Mkts
    5/22/2025$185.00Buy → Neutral
    Citigroup
    5/2/2025$185.00Overweight → Neutral
    Piper Sandler
    5/2/2025$192.00Buy → Neutral
    Goldman
    More analyst ratings

    $BDX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    BD Delivers Kidney Stone Care for Urology Teams with the Elyra™ Thulium Fiber Laser System

    New laser system is designed to help urology teams enhance efficiency, versatility, and procedural workflow across stone management and soft tissue procedures.FRANKLIN LAKES, N.J., May 21, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, today announced the introduction of the Elyra™ Thulium Fiber Laser (TFL) System, an advanced laser platform developed to complete BD's kidney stone care portfolio for urology teams. Designed to enhance efficiency, versatility, and procedural workflow across urologic stone management and soft tissue procedures, the innovative new system supports consistent performance in demanding clinical enviro

    5/21/26 6:50:00 AM ET
    $BDX
    Medical/Dental Instruments
    Health Care

    Peter Menziuso Named EVP and President, BD Interventional

    FRANKLIN LAKES, N.J., May 18, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, today announced that Peter Menziuso has been named executive vice president and president, BD Interventional, effective June 1. Menziuso brings more than 30 years of global healthcare leadership experience and a strong track record of driving growth through disciplined execution. He most recently served as Company Group Chairman of Johnson & Johnson Vision, where he led a $5 billion global business with responsibility for commercial opera

    5/18/26 6:50:00 AM ET
    $BDX
    Medical/Dental Instruments
    Health Care

    BD Appoints Vitor Roque Chief Financial Officer

    FRANKLIN LAKES, N.J., May 7, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, today announced that Vitor Roque has been named executive vice president and chief financial officer (CFO), effective May 7. Roque has served as interim CFO since December 2025. With more than 25 years at BD, Roque has held senior finance and operations roles across the company, most recently as senior vice president, Finance and Corporate Financial Planning and Analysis. During his tenure as interim CFO, he led BD's global finance functio

    5/7/26 6:31:00 AM ET
    $BDX
    Medical/Dental Instruments
    Health Care

    $BDX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Evercore ISI resumed coverage on Becton Dickinson with a new price target

    Evercore ISI resumed coverage of Becton Dickinson with a rating of Outperform and set a new price target of $180.00

    5/4/26 8:48:11 AM ET
    $BDX
    Medical/Dental Instruments
    Health Care

    Goldman resumed coverage on Becton Dickinson with a new price target

    Goldman resumed coverage of Becton Dickinson with a rating of Neutral and set a new price target of $167.00

    4/10/26 12:23:31 PM ET
    $BDX
    Medical/Dental Instruments
    Health Care

    Barclays resumed coverage on Becton Dickinson with a new price target

    Barclays resumed coverage of Becton Dickinson with a rating of Overweight and set a new price target of $202.00

    2/10/26 7:21:54 AM ET
    $BDX
    Medical/Dental Instruments
    Health Care

    $BDX
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    November 23, 2021 - Coronavirus (COVID-19) Update: November 23, 2021

    For Immediate Release: November 23, 2021 The U.S. Food and Drug Administration today announced the following actions taken in its ongoing response effort to the COVID-19 pandemic: On Nov. 22, the FDA authorized three over-the-counter (OTC) COVID-19 antigen diagnostic tests for people age 14 years or older with a self-collected nasal swab sample or people age 2 years or older when an adult collects the nasal swa

    11/23/21 3:16:12 PM ET
    $BDX
    Medical/Dental Instruments
    Health Care

    July 23, 2021 - Coronavirus (COVID-19) Update: July 23, 2021

    For Immediate Release: July 23, 2021 The U.S. Food and Drug Administration today announced the following actions taken in its ongoing response effort to the COVID-19 pandemic: The agency updated its FDA COVID-19 Response At-A-Glance Summary, which provides a quick look at facts, figures and highlights on the FDA's response efforts. On Thursday, July 22 the FDA issued an Emergency Use Authorization (EUA) to Bec

    7/23/21 4:06:11 PM ET
    $BDX
    Medical/Dental Instruments
    Health Care

    $BDX
    SEC Filings

    View All

    Becton Dickinson and Company filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - BECTON DICKINSON & CO (0000010795) (Filer)

    5/29/26 8:39:28 AM ET
    $BDX
    Medical/Dental Instruments
    Health Care

    SEC Form SD filed by Becton Dickinson and Company

    SD - BECTON DICKINSON & CO (0000010795) (Filer)

    5/22/26 1:24:24 PM ET
    $BDX
    Medical/Dental Instruments
    Health Care

    SEC Form CERT filed by Becton Dickinson and Company

    CERT - BECTON DICKINSON & CO (0000010795) (Filer)

    5/21/26 1:18:51 PM ET
    $BDX
    Medical/Dental Instruments
    Health Care

    $BDX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Hayes Gregory bought $1,005,742 worth of shares (5,250 units at $191.57), increasing direct ownership by 660% to 6,046 units (SEC Form 4)

    4 - BECTON DICKINSON & CO (0000010795) (Issuer)

    8/11/25 4:15:55 PM ET
    $BDX
    Medical/Dental Instruments
    Health Care

    Director Henderson Jeffrey William bought $350,430 worth of shares (1,500 units at $233.62), increasing direct ownership by 23% to 8,015 units (SEC Form 4)

    4 - BECTON DICKINSON & CO (0000010795) (Issuer)

    2/10/25 5:03:18 PM ET
    $BDX
    Medical/Dental Instruments
    Health Care

    $BDX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chairman, CEO and President Polen Thomas E Jr exercised 20,209 shares at a strike of $126.16, returned $2,549,587 worth of shares to the company (17,445 units at $146.15) and sold $404,511 worth of shares (2,764 units at $146.35) as part of a pre-agreed trading plan, increasing direct ownership by 4% to 110,163 units (SEC Form 4)

    4 - BECTON DICKINSON & CO (0000010795) (Issuer)

    6/3/26 12:44:24 PM ET
    $BDX
    Medical/Dental Instruments
    Health Care

    EVP and President, BDI Menziuso Peter was granted 14,258 shares (SEC Form 4)

    4 - BECTON DICKINSON & CO (0000010795) (Issuer)

    6/2/26 2:11:50 PM ET
    $BDX
    Medical/Dental Instruments
    Health Care

    New insider Menziuso Peter claimed no ownership of stock in the company (SEC Form 3)

    3 - BECTON DICKINSON & CO (0000010795) (Issuer)

    6/2/26 2:04:55 PM ET
    $BDX
    Medical/Dental Instruments
    Health Care

    $BDX
    Financials

    Live finance-specific insights

    View All

    BD Reports Second Quarter Fiscal 2026 Financial Results

    Revenue of $4.7 billion increased 5.2% as reported, 2.6% FXNGAAP and adjusted diluted EPS from continuing operations of $(0.13) and $2.90, respectivelyExecuted a $2.0 billion accelerated share repurchase (ASR) program and retired $2.1 billion of debt in the quarterCompany reaffirms revenue growth guidance, raises full-year adjusted diluted EPS guidance1FRANKLIN LAKES, N.J., May 7, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, today announced results for its fiscal 2026 second quarter, which ended March 31, 2026. "We delivered a solid second quarter, with revenue, margins and EPS all ahead of our expectations," said Tom Polen,

    5/7/26 6:30:00 AM ET
    $BDX
    Medical/Dental Instruments
    Health Care

    BD Board Declares Dividend

    FRANKLIN LAKES, N.J., April 28, 2026 /PRNewswire/ -- The Board of Directors of BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, today announced it has declared a quarterly dividend of $1.05 per common share, payable on June 30, 2026, to holders of record on June 9, 2026. The indicated annual dividend rate is $4.20 per share. About BDBD is one of the world's largest pure-play medical technology companies with a Purpose of advancing the world of health™ by driving innovation across medical essentials, connected care, biopharma systems and interventional. The company supports those on the frontlines of healthcare by developing transformative technologi

    4/28/26 4:15:00 PM ET
    $BDX
    Medical/Dental Instruments
    Health Care

    BD Reports First Quarter Fiscal 2026 Financial Results

    Revenue of $5.3 billion increased 1.6% as reported, 0.4% FXNNew BD revenue increased 2.5% FXNGAAP and adjusted diluted EPS of $1.34 and $2.91, respectivelyCombination of BD's Biosciences and Diagnostic Solutions business with Waters Corporation expected to close todayCompany affirms FY26 revenue growth guidance, provides Adjusted Diluted EPS guidance for New BDFRANKLIN LAKES, N.J., Feb. 9, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, today announced results for its fiscal 2026 first quarter, which ended December 31, 2025. "We delivered stronger‑than‑expected first‑quarter performance which reflects our disciplined execution

    2/9/26 6:30:00 AM ET
    $BDX
    Medical/Dental Instruments
    Health Care

    $BDX
    Leadership Updates

    Live Leadership Updates

    View All

    BD Appoints Vitor Roque Chief Financial Officer

    FRANKLIN LAKES, N.J., May 7, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, today announced that Vitor Roque has been named executive vice president and chief financial officer (CFO), effective May 7. Roque has served as interim CFO since December 2025. With more than 25 years at BD, Roque has held senior finance and operations roles across the company, most recently as senior vice president, Finance and Corporate Financial Planning and Analysis. During his tenure as interim CFO, he led BD's global finance functio

    5/7/26 6:31:00 AM ET
    $BDX
    Medical/Dental Instruments
    Health Care

    Waters Completes Combination with BD's Biosciences & Diagnostic Solutions Businesses

    Announces appointment of Claire M. Fraser, Ph.D., to its Board of DirectorsForms a global life sciences and diagnostics leader focused on high-volume testing in regulated applicationsAnnounces formation of four divisions: Waters Analytical Sciences, Waters Biosciences, Waters Advanced Diagnostics, and Waters Materials SciencesMILFORD, Mass., Feb. 9, 2026 /PRNewswire/ -- Waters Corporation (NYSE:WAT) ("Waters") today announced it has completed the previously announced combination with the Biosciences & Diagnostic Solutions businesses of Becton, Dickinson and Company (NYSE:BDX) ("BD"). The transaction forms a global life sciences and diagnostics leader, equipped with best-in-class technologies

    2/9/26 8:40:00 AM ET
    $BDX
    $WAT
    Medical/Dental Instruments
    Health Care
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    BD Appoints Robert Huffines and Jacqueline Wright to Board of Directors

    FRANKLIN LAKES, N.J., Nov. 17, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, today announced the appointment of Robert "Robbie" Huffines and Jacqueline "Jacky" Wright to its board of directors, effective Dec. 1, 2025. "Robbie and Jacky will further strengthen the BD board with deep expertise in health care, technology, digital transformation and artificial intelligence, as well as finance and capital markets, all of which are core to the continued advancement of our strategy," said Tom Polen, chairman, CEO and

    11/17/25 4:30:00 PM ET
    $BDX
    Medical/Dental Instruments
    Health Care

    $BDX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Becton Dickinson and Company (Amendment)

    SC 13G/A - BECTON DICKINSON & CO (0000010795) (Subject)

    2/16/24 4:29:42 PM ET
    $BDX
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by Becton Dickinson and Company (Amendment)

    SC 13G/A - BECTON DICKINSON & CO (0000010795) (Subject)

    2/14/24 10:02:59 AM ET
    $BDX
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by Becton Dickinson and Company (Amendment)

    SC 13G/A - BECTON DICKINSON & CO (0000010795) (Subject)

    2/13/24 5:00:53 PM ET
    $BDX
    Medical/Dental Instruments
    Health Care